<DOC>
	<DOC>NCT02184364</DOC>
	<brief_summary>To investigate, relative to placebo and conjugated oestrogens, the efficacy, safety and tolerability of a 12 weeks peroral treatment twice daily with a cimicifuga racemosa extract corresponding to 20 mg, 75 mg or 150 mg plant material on menopause-related neurovegetative and mental complaints</brief_summary>
	<brief_title>Klimadynon® in Comparison to Conjugated Oestrogens in Women Suffering From Menopausal Complaints</brief_title>
	<detailed_description />
	<mesh_term>Estrogens, Conjugated (USP)</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Only postmenopausal (amenorrhea for 6 months at least) women may be enrolled in the study Women after ovariectomy may also be enrolled if surgery was carried out at least 6 months prior to the enrollment. Only women between the age of 40 and 60 may be included 2 weeks (control 1, week 2, day 14) before the beginning of the treatment the following hormone values must have been analyzed: estradiol17ß ≤ 0.15 nmol/l corresponding to ≤ 40 pg/ml and follicle stimulating hormone (FSH) ≥ 25 milliunits per milliliter (mU/ml) These hormone analyses must be carried out at the competent local laboratory In addition to other menopausal complaints the women must have hot flushes / outbreaks of sweating: Diary: During the "runin period" daily ≥ 3 hot flushes / outbreaks of sweating Modified Menopause Rating Scale, 1st item twofold (week 2 and 0) ≥ 0.3 A sum score taken twice from the modified (only items 1 6) Menopause Rating Scale within 2 weeks (week 1 and 0) before the beginning of treatment must be ≥ 1.7 In case of a pretreatment with estrogen a washout phase of 6 weeks is necessary in case of oral or transdermal administration. After the 4th week of washout the patient may be included in the "runin period" General criteria for exclusion: Nonresponder (= no therapeutic success) under a pretreatment with estrogen Amenorrhea for &lt; 6 months In case of an estrogen pretreatment last menstruation (menopause) &gt; 3 years earlier Sum score of the modified Menopause Rating Scale (items 1 6) during the "runin period" twice (week 2 and 0) &lt; 1.7 No hot flushes / outbreaks of sweating (see Inclusion criteria) At one of the appointments of the "runin period" (week 2 and 0) more than one question of items 1 6 of the modified Menopause Rating Scale (MMRS) not answered During the "runin period" at the appointment week 2: estradiol17ß &gt; 40 pg/ml corresponding to &gt; 0.15 nmol/l and FSH &lt; 25 mU/ml Condition after hysterectomy Simultaneous ingestion of estrogencontaining products in addition to the test products Any addition ingestion of psychotropic drugs, antidepressants and sleeping aids (hypnotics / sedatives) Treatment with another study drug in the 2 months preceding the beginning of the study Considerable overweight (exceeding the target body weight [height in cm minus 100] by more than 30%) Poor general condition Alcohol or drug abuse Poor compliance Exclusion criteria based on conjugated estrogens or medroxyprogesterone: Any contraindication for estrogen Unresolved genital bleeding Suspicion / existence of estrogendependent mammary carcinoma (mammography and/or endometrial carcinoma) Endometriosis Endometrial hyperplasia (including hyperplastic polypoid endometrium, which has not yet reached the stage of a glandular cystic hyperplasia) Thickness of endometrium &gt; 5 mm Existing thromboembolism or thromboembolism in the past Phlebitis in the past 2 years or actually existing Acute or chronic hepatic lesion (aspartate transaminase and/or alanine transaminase and/or gamma glutamyl transferase twice the normal range) Metabolic disorders of bile pigments (DubinJohnson's syndrome, Rotor syndrome, pregnancy icterus with/without pruritus in previous pregnancy) Sickle cell anemia Clinically relevant hypertriglyceridemia or hypercholesterolemia Heart attack in the past Severe varicosis Known sensitivity to medroxyprogesterone Case history of anaphylactic reaction Any neoplasm at the genitals Case history of antidepressant treatment Diabetes mellitus with or without treatment</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>